Literature DB >> 16303623

Urinary leukotriene E4 excretion is increased in type 1 diabetic patients: a quantification by liquid chromatography-tandem mass spectrometry.

Gaëlle Hardy1, Robert Boizel, Janine Bessard, Jean-Luc Cracowski, Germain Bessard, Serge Halimi, Françoise Stanke-Labesque.   

Abstract

OBJECTIVE: Diabetes mellitus is associated with inflammatory state and increased cardiovascular mortality. Leukotrienes are arachidonic acid metabolites derived from the 5-lipoxygenase pathway that possess vasoactive, chemotactic and proinflammatory properties. The aim of this study was to evaluate (1) the urinary excretion of leukotriene E4 (LTE4) in type 1 diabetic subjects and healthy volunteers and (2) the influence of glycemic control attested by HbA(1C) on LTE4 excretion. METHODS AND
RESULTS: Urinary excretion of LTE(4), measured by liquid chromatography-tandem mass spectrometry, was significantly (P=0.033) increased in diabetic patients (median [10th-90th percentiles]: 42.1 pg/mg creatinine [16.7-71.4], n=34), compared to healthy subjects (25.5 pg/mg creatinine [13.9-54.1], n=28). Subgroup analysis indicated a trend towards increased LTE4 excretion in patients with poor glycemic control [(HbA(1C)> or =9% or plasma glucose >18 mmol/L): 43.3 pg/mg creatinine [21.6-70.5], n=14], whereas no difference was observed between patients with good metabolic control [(HbA(1C)< or =7.5%): 36.4 pg/mg creatinine [15.8-83.4], n=20] and healthy subjects.
CONCLUSIONS: This study suggested that increased LTE4 excretion in type 1 diabetic state might reflect systemic activation of the 5-lipoxygenase pathway. It could be a determinant of underlying inflammatory state and vascular disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16303623     DOI: 10.1016/j.prostaglandins.2005.10.001

Source DB:  PubMed          Journal:  Prostaglandins Other Lipid Mediat        ISSN: 1098-8823            Impact factor:   3.072


  7 in total

1.  Regulation of oxidative stress and inflammation by glycaemic control: evidence for reversible activation of the 5-lipoxygenase pathway in type 1, but not in type 2 diabetes.

Authors:  R Boizel; G Bruttmann; P Y Benhamou; S Halimi; F Stanke-Labesque
Journal:  Diabetologia       Date:  2010-06-10       Impact factor: 10.122

Review 2.  Lipid deposition and metaflammation in diabetic kidney disease.

Authors:  Alla Mitrofanova; Antonio M Fontanella; Sandra Merscher; Alessia Fornoni
Journal:  Curr Opin Pharmacol       Date:  2020-11-01       Impact factor: 5.547

Review 3.  Analysis of endogenous glutathione-adducts and their metabolites.

Authors:  Ian A Blair
Journal:  Biomed Chromatogr       Date:  2010-01       Impact factor: 1.902

4.  Leukotriene-E4 in human urine: Comparison of on-line purification and liquid chromatography-tandem mass spectrometry to affinity purification followed by enzyme immunoassay.

Authors:  Michael Armstrong; Andrew H Liu; Ronald Harbeck; Rick Reisdorph; Nathan Rabinovitch; Nichole Reisdorph
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2009-08-18       Impact factor: 3.205

5.  Leukotriene production is increased in abdominal obesity.

Authors:  Magnus Bäck; Antoine Avignon; Françoise Stanke-Labesque; Catherine Boegner; Vincent Attalin; Elodie Leprieur; Ariane Sultan
Journal:  PLoS One       Date:  2014-12-01       Impact factor: 3.240

6.  Resolvin D1 Decreases Severity of Streptozotocin-Induced Type 1 Diabetes Mellitus by Enhancing BDNF Levels, Reducing Oxidative Stress, and Suppressing Inflammation.

Authors:  Siresha Bathina; Undurti N Das
Journal:  Int J Mol Sci       Date:  2021-02-03       Impact factor: 5.923

7.  Urinary leukotriene E4 is associated with renal function but not with endothelial function in type 2 diabetes.

Authors:  Arnar Rafnsson; Magnus Bäck
Journal:  Dis Markers       Date:  2013-10-02       Impact factor: 3.434

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.